Changchun High-Tech Industry (Group) Co., Ltd. Share Price
Equities
000661
CNE0000007J8
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 86.59 CNY | -0.96% |
|
+1.95% | -6.44% |
| 05-07 | Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug | MT |
| 05-07 | Changchun High-Tech Gets Approval for Clinical Trial of GenSci155 | MT |
| Capitalization | 34.78B 5.11B 4.35B 3.98B 3.75B 7B 483B 7.06B 47.18B 18.39B 232B 19.19B 18.79B 801B | P/E ratio 2026 * |
30.7x | P/E ratio 2027 * | 19.2x |
|---|---|---|---|---|---|
| Enterprise value | 34.78B 5.11B 4.35B 3.98B 3.75B 7B 483B 7.06B 47.18B 18.39B 232B 19.19B 18.79B 801B | EV / Sales 2026 * |
3.16x | EV / Sales 2027 * | 2.69x |
| Free-Float |
68.28% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -0.96% | ||
| 1 week | +1.95% | ||
| Current month | +1.95% | ||
| 1 month | +0.69% | ||
| 3 months | -3.01% | ||
| 6 months | -17.58% | ||
| Current year | -6.44% |
| 1 week | 84.92 |  | 87.9 |
| 1 month | 84.75 | | 88.5 |
| Current year | 83.75 | | 106.65 |
| 1 year | 83.75 | | 141.77 |
| 3 years | 77.5 | | 175.8 |
| 5 years | 77.5 | | 523 |
| 10 years | 43.95 | | 523 |
| Manager | Title | Age | Since |
|---|---|---|---|
Lei Jin
CEO | Chief Executive Officer | 61 | 10/09/2024 |
Xing Gong Zhu
DFI | Director of Finance/CFO | 60 | 24/05/2005 |
Peng Ye
PRN | Corporate Officer/Principal | 59 | 23/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Xiu Feng Li
CHM | Chairman | 58 | 31/07/2008 |
Zhi Gang Wang
BRD | Director/Board Member | 54 | 28/12/2014 |
Yun Tao Jiang
CHM | Chairman | 52 | 23/06/2024 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.96% | +1.95% | -9.61% | -46.37% | 5.11B | |
| +0.82% | +1.92% | +35.45% | -4.63% | 72.73B | |
| -0.09% | +2.36% | +47.71% | +176.35% | 52.45B | |
| +0.27% | +47.20% | +47.20% | +47.20% | 46.63B | |
| -15.96% | -19.01% | -57.15% | -66.64% | 42.13B | |
| +1.08% | +3.42% | +63.70% | -38.25% | 28.56B | |
| +11.97% | +19.79% | +124.12% | -58.46% | 21.57B | |
| -1.94% | -4.54% | +78.64% | +126.28% | 19.95B | |
| +0.81% | +1.70% | +67.11% | +54.19% | 19.69B | |
| +1.29% | +1.99% | +45.06% | +89.18% | 16.32B | |
| Average | -0.70% | +2.73% | +44.22% | +27.89% | 32.51B | |
| Weighted average by Cap. | -1.31% | +1.96% | +39.82% | +33.09% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 11.01B 1.62B 1.38B 1.26B 1.19B 2.22B 153B 2.24B 14.94B 5.82B 73.47B 6.08B 5.95B 254B | 12.93B 1.9B 1.61B 1.48B 1.39B 2.6B 180B 2.63B 17.53B 6.83B 86.23B 7.13B 6.98B 298B |
| Net income | 1.15B 169M 144M 132M 124M 232M 15.98B 234M 1.56B 608M 7.67B 635M 621M 26.49B | 1.84B 271M 230M 211M 199M 371M 25.58B 374M 2.5B 974M 12.29B 1.02B 995M 42.42B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/05/26 | 86.59 ¥ | -0.96% | 4,671,405 |
| 07/05/26 | 87.43 ¥ | +2.39% | 7,235,842 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Equities
- 000661 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition